The UK authorities has bought one other 60 million doses of the Pfizer/BioNTech Covid-19 vaccine to assist its booster program for the autumn, the Division of Well being introduced on Wednesday.
“Our vaccination program is bringing again our freedom, however the greatest threat to that progress is the chance posed by a brand new variant,” Well being Secretary Matt Hancock mentioned in a press release.
“We’re engaged on our plans for booster photographs, that are one of the simplest ways to maintain us secure and free whereas we get this illness below management throughout the entire world.
“These additional 60 million doses will likely be used, alongside others, as a part of our booster program from later this yr, so we will defend the progress that we’ve all made,” Hancock mentioned.
Over 1 / 4 of the UK’s inhabitants — 13,581,076 individuals — have obtained two doses of a Covid-19 vaccine, and greater than 33 million individuals have obtained a primary dose, in line with figures from the Division of Well being.
In complete, the UK has secured entry to 517 million doses of eight Covid-19 vaccine candidates, nonetheless not all of those have but been authorised by the nation’s medicines regulator (MHRA). Rolling critiques are underway by the MHRA to evaluate the Janssen and Novavax vaccines and medical trials are ongoing for the Valneva, GSK and Sanofi and CureVac vaccines.
The main points are as follows:
- Pfizer/BioNTech for 100 million doses, together with the extra 60 million doses
- Oxford/AstraZeneca for 100 million doses
- Moderna for 17 million doses
- Janssen for 30 million doses
- Novavax for 60 million doses
- Valneva for 100 million doses
- GlaxoSmithKline and Sanofi Pasteur for 60 million doses
- CureVac for 50 million doses